Artichoke Leaf Extract: Digestive Trials and Safety

Artichoke leaf extract has a preliminary dyspepsia signal from a manufacturer-sponsored trial, rated low certainty by Cochrane. IBS reports lack placebo controls and complete diagnostic safeguards. Liver studies are small and short; one has allocation and participant-reporting problems, and another shows time-specific imaging changes alongside a higher AST marker. Commercial relationships and unknown procurement terms remain distinct. Specified traditional medicines have important biliary, liver, allergy and medication restrictions. These findings do not establish SIBO treatment, a liver detox, universal product equivalence or a safe general dose.

Resistant Starch: Forms, Clinical Evidence and Safety

Resistant starch preparations and doses are not interchangeable. The reviewed constipation and IBS studies do not establish a dependable general supplement treatment. One IBS blend’s anxiety finding fails adjustment for multiple comparisons; another blend used an RS-rich comparator. A controlled-feeding trial found a short-term weight difference with regain during washout. Hospital rehydration and Lynch-syndrome cancer findings apply to narrow clinical settings. Company funding, supplied materials, university IP and commercial author affiliations are disclosed; unknown payment terms remain unknown.

Inulin: Bowel Regularity, IBS Evidence and Digestive Tolerance

Inulin is a fermentable fiber with some positive bowel trials and a defined European food claim. Results differ by preparation and population; major positive studies have commercial support, and small samples, carryover and analysis limits matter. A blend’s IBS symptom signal and reduced MRI gas do not establish isolated-inulin treatment or lasting symptom relief. The pediatric agave trial improved hard-stool consistency without establishing a frequency benefit. Gas and tolerance vary. Funding and procurement limits remain explicit, and the research doses are not a general treatment regimen.

Partially Hydrolyzed Guar Gum (PHGG): Constipation, IBS Evidence and Tolerability

PHGG differs physically from intact guar gum and provides soluble fiber with less thickening. Some trials report narrow bowel signals, but small samples, attrition, commercial support and incomplete reporting limit generalization. The reviewed evidence does not establish a dependable general regimen for IBS, constipation, diarrhea or gut repair. Microbiome changes are not clinical recovery, and tolerance varies. Named funding and product supply are retained separately from unknown donor allocations or purchase terms. Research doses are not instructions to replace care.

One daily research roundup

Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.

Confirm through your inbox. Unsubscribe anytime. Research only; Shop updates have a separate signup. Please do not send health information.